Rogel team receives $11.2M to leverage the microbiome against GVHD

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of researchers from the University of Michigan Rogel Cancer Center received a $11.2 million grant from the National Heart, Lung and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login